p53 protein expression in laryngeal squamous cell carcinomas bearing wild-type and mutated p53 gene

Histopathology

Volumn 28, Issue 6, 1996, Pages 513-519

  Pruneri, G ^a   Pignataro, L ^a   Fracchiolla, N S ^a   Ferrero, S ^a   Capaccio, P ^a   Carboni, N ^a   Ottaviani, A ^a   Maiolo, A T ^a   Neri, A ^a   Buffa, R ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b Istituto di Anatomia Patologica   (Italy)

Author keywords

Laryngeal squamous cell carcinoma; p53 gene mutation; p53 protein expression

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; MALE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

EID: 8944234857     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1996.d01-466.x     Document Type: Article

References (49)

1. Stringer SP, In Meyerhoff WL, Rice DH eds. Otolaryngology Head and Neck Surgery. Harcourt Brace, Jovanovich: WB Saunders Company, 1992; 739-760.
2. Batsakis JG. Tumors of head and neck: clinical and pathological considerations. Baltimore: Williams and Wilkins, 1979; 574.
3. Jussawalla DJ, Deshpande VA. Evaluation of cancer risk in tobacco chewers and smokers: an epidemiologic assessment. Cancer 1971; 28; 244-252.
4. Rothman K, Keller A. The effect of joint exposure to alcohol and tobacco risk on cancer of the mouth and pharynx. J. Chron. Dis. 1972; 25; 711-716.
5. Johnson NW. Oro-facial neoplasms: global epidemiology, risk factors and reccomendations for research. In FDI Technical report 36 Federation Dentaire Internationale, London, 1990.
6. Stevens J. Synergistic effect of alcohol on epidermoid carcinogenesis in the larynx. Otolaryngol. Head and Neck Surg 1979; 87; 751-756.
7. Goldsmith MM, Pillsbury HC. Pathologic and cytometric indicators of biologic behaviour in laryngeal cancer. In Silver CE ed. Laryngeal cancer. New York: Thieme Medical Publisher, 1991; 27-32.
8. Barnes L, Johnson J. Pathologic and clinical considerations in the evaluation of major head and neck specimens resected for cancer. Pathol. Annu. 1986; 21; 173-250.
9. Nigro JM, Baker SJ, Preisinger AC et al. Mutations in the p53 gene occur in diverse human tumor types. Nature 1989; 342; 705-708.
10. Hsu I, Metcalf R, Sun T, Welsh J, Wang N, Harris C. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350; 427-428.
11. Baker SJ, Fearon ER, Nigro JM et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinoma. Science 1989; 244; 217-221.
12. Prosser J, Thompson AM, Granston G, Evans HJ. Evidence that p53 behaves as a tumor suppressor gene in sporadic breast tumors. Oncogene 1990; 5; 573-1579.
13. Takahashi T, Nau MM, Chiba I et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989; 246; 491-494.
14. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancer. Science 1991; 253; 49-53.
15. Farmer G, Bargonetti J, Xhu H et al. Wild-type p53 activates transcription in vitro. Nature 1992; 358; 83-86.
16. Kern SK, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992; 256; 827-832.
17. Martinez J, Georgoff I, Martinez J, Levine AJ. Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev. 1991; 5; 151-159.
18. Hunter T, Braking the cycle. Cell 1993; 75; 839-841.
19. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74; 957-967.
20. Lavigueur A, Maltby V, Mock D, Rossant J, Pawson T, Bernstein A. High incidence of lung, bone and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol. Cell Biol. 1989; 9; 3982-3991.
21. Soussi T, Caron de Fromentel C, May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogence 1990; 5; 945-952.
22. Fracchiolla NS, Pignataro L, Capaccio P, Trecca D, Boletini A, Ottaviani A, Polli E, Maiolo AT, Neri A. Multiple genetic lesions in laryngeal squamous cell carcinomas. Cancer 1995; 75; 1292-1301.
23. Sakai E, Rikimaru K, Ueda M, Matsumoto Y, Ishii N, Enomoto S, Yamamoto H, Tsuchida N. The p53 suppressor gene and ras oncogene mutations in oral squamous cell carcinoma. Int. J. Cancer 1992; 52; 867-872.
24. Brachman DG, Beckett M, Graves D, Haraf D, Vokes E, Weichselbaum RR. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res. 1993; 53; 3667-3669.
25. Boyle JO, Hakim J, Koch W et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 1993; 53; 4817-4822.
26. Chung KY, Mukhopadhyay T, Kim J et al. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Cancer Res. 1993; 53; 1676-1683.
27. Ahomadegbe JC, Barrois M, Fogel S, Le Bihan ML, Douc-Rasy S, Duvillard P, Armand JP, Riou G. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumours and metastases: absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 1995; 10; 1217-1227.
28. Maestro R, Dolcetti R, Gasparotto D et al. High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene 1992; 7; 1159-1166.
29. Dolcetti R, Doglioni C, Maestro R et al. p53 over-expression is an early event in the development of human squamous-cell carcinoma of the larynx: genetic and prognostic implications. Int. J. Cancer 1992; 52; 178-182.
30. Nees M, Homann N, Discher H et al Expression of mutated p53 occurs in tumour-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumours. Cancer Res. 1993; 53; 4189-4196.
31. Shin DM, Kim J, Ro JY et al. Activation of p53 gene expression in premalignant lesions during head and neck tumourigenesis. Cancer Res. 1994; 54; 321-326.
32. Sakai E, Tsuchida N. Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumour-suppressor genes. Oncogene 1992; 7; 927-933.
33. Xhang W, Hu G, Estey E, Hester J, Deisseroth A. Altered conformation of the p53 protein in myeloid leukemia cells and mitogen-stimulated normal blood cells. Oncogene 1992; 7; 1645-1647.
34. UICC. TNM classification of malignant tumours. In Hermanek P, Sobin LH eds. Berlin: Springer Verlag, 1987.
35. Shanmugaratnam K, Sobin IN et al. Histological typing of tumours of the upper respiratory tract and ear. Geneva: WHO, 1991.
36. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC): a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem. 1981; 29; 577-580.
37. Nishioka H, Hiasa Y, Hayashi I, Kitahori Y, Konishi N, Sugimura M. Immunohistochemical detection of p53 oncoprotein in human oral squamous cell carcinomas and leukoplakias: comparison with proliferating cell nuclear antigen staining and correlation with clinicopathological findings. Oncology 1993; 50; 426-429.
38. Zambetti GP, Levine AJ. A comparison of the biological activities of the wild-type and mutant p53. FASEB J. 1993; 7; 855-865.
39. Ory K, Legros Y, Auguin C, Soussi T. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. Embo J. 1994; 13; 3496-3504.
40. Jolly KW, Malkin D, Douglass EC, Brown TF, Sinclair AE, Look AT. Splice- site mutation of the p53 gene in a family with hereditary breast-ovarian cancer. Oncogene 1994; 9; 97-102.
41. Felix CA, Strauss EA, D'Amico D et al. A novel germ-line splicing mutation in a pediatric patient with a second malignant neoplasm. Oncogene 1993; 8; 1203-1210.
42. Bargonetti J, Friedman PN, Kern SE, Vogelstein B, Prives C. Wild-type but not mutant p53 immunopurified proteins binds to sequences adjacent to the SV40 origin of replication. Cell 1991; 65; 1083-1091.
43. Helland A, Holm R, Kristensen G et al. Genetic alterations of the TP53 gene, p53 protein expression and HPV. J. Pathol. 1993; 171; 105-114.
44. Riou G, Barrois M, Prost S, Terrier MJ, Theodore C, Levine AJ. The p53 and mdm-2 genes in human testicular germ-cell tumors. Mol. Carcin. 1995; 12; 124-131.
45. Field JK, Spandidos SA, Malliri A, Gosney JR, Yiagnisis R, Stell PM. Elevated p53 expression correlates with a history of heavy smoking in squamous cell carcinomas of the head and neck. Br. J. Cancer 1991; 64; 573-577.
46. Gusterson BA, Anbazhagan R, Warren W et al.Expression of p53 in premalignant and malignant squamous epithelium. Oncogene 1991; 6; 1785-1789.
47. Anwar K, Nakakuki K, Imai H, Naiki H, Inuzuka M. Overexpression of p53 protein in human laryngeal carcinoma. Int. J. Cancer 1993; 53; 952-956.
48. Bourhis J, Bosq J, Wilson GD et al. Correlation between p53 gene expression and tumor-cell proliferation in oropharyngeal cancer. Int. J. Cancer 1994; 57; 458-462.
49. Frank JL, Bur ME, Garb JL, Kay S, Ware JL, Sismanis A, Neifeld JP. p53 tumor suppressor oncogene expression in squamous cell carcinoma of the hypopharynx. Cancer 1994; 73; 181-186.